Harvard Bioscience, Inc. (NASDAQ:HBIO) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) have earned a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. Harvard Bioscience’s rating score has declined by 100% from three months ago as a result of a number of analysts’ upgrades and downgrades.

Brokerages have set a 12-month consensus price target of $2.50 for the company and are expecting that the company will post $0.04 earnings per share for the current quarter, according to Zacks. Zacks has also given Harvard Bioscience an industry rank of 110 out of 256 based on the ratings given to its competitors.

HBIO has been the topic of several research reports. Zacks Investment Research downgraded Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Benchmark reissued a “buy” rating on shares of Harvard Bioscience in a research report on Friday, July 19th. ValuEngine raised Harvard Bioscience from a “sell” rating to a “hold” rating in a research report on Monday, August 12th. Finally, Janney Montgomery Scott downgraded Harvard Bioscience from a “buy” rating to a “neutral” rating and set a $2.00 target price on the stock. in a research report on Monday, July 8th.



In related news, Director Katherine A. Eade purchased 39,915 shares of the business’s stock in a transaction on Friday, August 9th. The shares were bought at an average cost of $2.48 per share, with a total value of $98,989.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO James W. Green purchased 20,000 shares of the business’s stock in a transaction on Friday, August 9th. The shares were bought at an average cost of $2.47 per share, for a total transaction of $49,400.00. The disclosure for this purchase can be found here. 5.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in HBIO. Tower Research Capital LLC TRC grew its position in Harvard Bioscience by 401.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,752 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 11,011 shares during the period. BNP Paribas Arbitrage SA grew its position in shares of Harvard Bioscience by 635.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,567 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 6,538 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Harvard Bioscience during the 2nd quarter valued at about $34,000. Jefferies Group LLC acquired a new stake in shares of Harvard Bioscience during the 2nd quarter valued at about $36,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Harvard Bioscience during the 2nd quarter valued at about $118,000. 76.39% of the stock is currently owned by institutional investors.

Shares of NASDAQ HBIO traded down $0.03 during mid-day trading on Thursday, hitting $2.47. The stock had a trading volume of 159,700 shares, compared to its average volume of 524,928. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.12 and a current ratio of 2.52. The company has a 50 day moving average of $2.15 and a two-hundred day moving average of $3.02. Harvard Bioscience has a twelve month low of $1.51 and a twelve month high of $6.55. The firm has a market cap of $95.11 million, a PE ratio of 25.00 and a beta of 1.51.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.01. Harvard Bioscience had a positive return on equity of 5.24% and a negative net margin of 0.46%. The firm had revenue of $29.58 million for the quarter, compared to the consensus estimate of $29.30 million. Equities research analysts predict that Harvard Bioscience will post 0.11 EPS for the current fiscal year.

About Harvard Bioscience

Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.

Featured Article: Inverted Yield Curve

Get a free copy of the Zacks research report on Harvard Bioscience (HBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.